![]() | |
Discipline | Oncology |
---|---|
Language | English |
Edited by | Adrian L Harris |
Publication details | |
History | 1947–present |
Publisher | |
Frequency | 24/year |
After 12 months | |
License | CC-BY-NC-SA 3.0 (1999+) |
9.0 (2021) | |
Standard abbreviations | |
ISO 4 | Br. J. Cancer |
Indexing | |
ISSN | 0007-0920 (print) 1532-1827 (web) |
Links | |
The British Journal of Cancer (BJC) is a twice-monthly professional medical journal published by Springer Nature's Nature Research.
The BJC provides a forum for clinicians and scientists to communicate original research findings that have relevance to understanding the etiology of cancer and to improving patient treatment and survival. Once accepted, papers are published in print and online.
Full research papers are published under six broad headings:
The journal was founded in 1947 by the then British Empire Cancer Campaign (later named Cancer Research Campaign), [1] one of the research charities which later merged to form Cancer Research UK. Cancer Research Campaign began partnering with Nature as publisher of the journal in the 1980s, but retained ownership and editorial control. In 2021, after the charity experienced a fall in charitable income during the COVID-19 pandemic, Cancer Research UK sold the journal to Springer Nature. [2]
According to the Journal Citation Reports , the journal received an impact factor of 9.0, [3] ranking it 39th journals in the category of Oncology. [4] SJR ranked BJC as 30th journal in cancer research with H-index 224. [5]
BJC is a top cited general cancer journal committed to publishing cutting edge discovery, translational and clinical cancer research. [6] The journal is indexed in:
The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI), which came into operation 1 April 2018, and brings together the UK's seven research councils, Innovate UK and Research England. UK Research and Innovation is answerable to, although politically independent from, the Department for Business, Energy and Industrial Strategy.
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 58,000 members in 142 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Nature Medicine is a monthly peer-reviewed medical journal published by Nature Portfolio covering all aspects of medicine. It was established in 1995. The journal seeks to publish research papers that "demonstrate novel insight into disease processes, with direct evidence of the physiological relevance of the results". As with other Nature journals, there is no external editorial board, with editorial decisions being made by an in-house team, although peer review by external expert referees forms a part of the review process. The editor-in-chief is João Monteiro.
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
Allied Academies is a reportedly fraudulent corporation chartered under the laws of North Carolina. Its postal address is in London, United Kingdom. It presents itself as an association of scholars, with supporting and encouraging research and the sharing and exchange of knowledge as its stated aims. The organization consists of 30 affiliate academies, which provide awards to academics and publish academic journals both online and in hard copy for members. Since 2015 the organization has been listed on Jeffrey Beall's list of "potential, possible, or probable predatory scholarly open-access publishers". It is in a partnership with OMICS Publishing Group which uses its website and logo. In 2018, OMICS owner Srinubabu Gedela declared that he had informed the Nevada court that Allied Academies was a subsidiary of OMICS International. During a conference in 2018, they falsely listed a prominent chemist among its organizing committee who had not agreed to this and was not affiliated with Allied Academies.
Oncogene is a peer-reviewed scientific journal published under the Nature Portfolio addressing cancer cell genetics and the structure and function of oncogenes. The journal has editorial office in London, England under the publishing company Springer Nature. The journal was established in 1987. An open access online-only sister journal, Oncogenesis, was established in 2012 by Douglas R. Green, who was then Oncogene's editor-in-chief.
Clinical Cancer Research is a peer-reviewed medical journal on oncology, including the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer, medical and hematological oncology, radiation therapy, pediatric oncology, pathology, surgical oncology, and clinical genetics. The applications of the disciplines of pharmacology, immunology, cell biology, and molecular genetics to intervention in human cancer are also included. One of the main interests of Clinical Cancer Research is on clinical trials that evaluate new treatments together with research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. Another priority for Clinical Cancer Research is laboratory and animal studies of new drugs as well as molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. The journal is published by the American Association for Cancer Research.
The Journal of NeuroVirology is a medical journal that publishes review articles on the molecular biology, immunology, genetics, epidemiology, and pathogenesis of CNS disorders with the goal of bridging the gap between basic and clinical studies, and enhancing translational research in neurovirology. It is published by Springer Science+Business Media. The Journal of NeuroVirology is the official journal of the International Society for Neurovirology.
Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London. Prof Gabra currently practises as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust, acting as Lead Clinician for Cancer Services.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
The Journal of the American College of Cardiology is a peer-reviewed medical journal covering all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the-art papers, review articles, and editorials interpreting and commenting on the research presented, published by the American College of Cardiology.
Molecular Oncology is a monthly peer-reviewed open-access medical journal covering research in molecular oncology. It is published by Wiley on behalf of the Federation of European Biochemical Societies. The journal regularly publishes thematic issues with review articles focusing on specific topics of basic, translational, or clinical cancer research. According to the Journal Citation Reports, the journal has a 2022 impact factor of 6.6
The Atlas of Genetics and Cytogenetics in Oncology and Haematology, created in 1997 by Jean-Loup Huret is a collection of resources on genes, chromosomes anomalies, leukemias, solid tumours, and cancer-prone diseases. The project is accessible through Internet and is made of encyclopedic-style files, as well as traditional overviews, links towards websites and databases devoted to cancer and/or genetics, case reports in haematology. It also encompasses teaching items in various languages.
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang. The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").
The Edinburgh Cancer Research Centre (ECRC), also known as the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.
Sun Yat-sen University Cancer Center, abbreviated as SYSUCC, is a public hospital in Guangzhou, China. It is affiliated with Sun Yat-sen University.
Marc Tischkowitz is a British medical geneticist. He is a Professor and Head of the Department of Medical Genetics at University of Cambridge. He also works as an Honorary NHS Consultant in the East Genomic Medicine Service. He is editor-in-chief of BJC Reports and NIHR CRN East of England Specialty Lead for Genetics. Tischkowitz researches Fanconi Anemia genes, hereditary cancer syndromes, and genomic technologies.